Latest News and Press Releases

Data from ongoing Actimab-A Phase 2 clinical trial highlighting efficacy, safety profile and clinical strategy as a single agent targeting CD33 in patients with AMLStudies highlighting enhanced...

- Current clinical trial sites represent approximately one third of bone marrow transplant volume in the U.S. - Actinium to provide update on SIERRA clinical trial by year-end NEW YORK, Oct. 25,...

- Actinium to present on Tuesday, October 17th at 3 PM PT NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...

- Phase 2 clinical trial is currently active at 16 clinical trial sites in the United States, surpassing the 10 clinical trial sites that were planned for the trial - Actinium affirms guidance for...

- Actinium is now a member of the ASBMT™ Corporate Council - Two day event focused on facilitating dialogue aimed at advancing the field of bone marrow transplantation and cellular therapy NEW YORK,...

- Company’s Actimab-A and Actimab-M programs to be presented at the conference NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc (NYSE American:ATNM) (“Actinium” or “the...

NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...

NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...

Actinium raised total gross proceeds of $16.125 million NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...

NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...